Cytokinetics, Inc.

Cytokinetics, Incorporated is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative muscle activators and inhibitors. Its primary mission is to address diseases marked by impaired or declining muscle performance, targeting both cardiac and skeletal muscle disorders. Cytokinetics’ research is at the forefront of muscle biology, with a robust pipeline focusing on small molecule drug candidates designed to modulate muscle function and contractility. Key programs include aficamten, a next-generation cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, along with other candidates targeting various forms of heart failure and muscular dystrophy. Founded in South San Francisco by experts in muscle biology, the company has grown over 25 years to become a leader in developing therapies for cardiovascular and neuromuscular diseases. Cytokinetics is recognized for its late-stage development capabilities, significant clinical trial activity, and global collaborations with pharmaceutical partners. Its contributions are particularly notable in the healthcare and biotechnology sectors, addressing unmet medical needs and improving quality of life for patients with debilitating muscle-related conditions.